AstraZeneca is making an additional investment of USD 135 million in its facility for biologics in Södertälje.
“We are happy about this investment in Södertälje, which demonstrates AstraZeneca’s commitment to innovation and manufacturing of biological medicines in Sweden,” says Per Alfredsson, CEO of AstraZeneca AB and Senior Vice President for Global Biologics Operations.
The investment includes an expansion of 2,700 square meters of an existing AstraZeneca building in Södertälje, which increases its area by 50 percent. AstraZeneca plans to begin manufacturing products for patients in the expanded facility as early as the fourth quarter of 2027. The investment includes the installation of new equipment for filling biological drugs into prefilled syringes.
New job opportunities
The planned expansion creates new job opportunities and underlines the company’s commitment to economic growth and job creation in the region, it states.
“The planned expansion will strengthen our ability to deliver high-quality, life-changing medicines to patients worldwide. It is also an expression of the confidence we have in the competence and potential that exists in the region,” says Alfredsson.
Photo of Per Alfredsson: AstraZeneca
